About us
Ulrike Protzer, MD, PhD
Scientific Founder
Professor Ulrike Protzer, a leading expert in Virology, is SCG's Scientific Co-founder and a member of the Board of Directors. She oversees SCG's scientific direction and collaboration with leading scientists and researchers to bring first-in-class and best-in-class medical products/technologies to enhance innovation in medical product development.
Professor Protzer currently serves as a Director of Institute of Virology at The Technical University of Munich and German Research Center for Environmental Health, Helmholtz Zentrum München. In addition, Professor Protzer serves in various roles as chair and a member of advisory boards of multiple research institutes and governmental agencies.
Professor Protzer also has published more than 600 scientific articles in the field of virology.
MANAGEMENT TEAM
Ke Zhang, PhD
Chief Scientific Officer
Dr. Ke Zhang is SCG’s Chief Scientific Officer and a member of the Board of Directors. Before joining SCG, Dr. Zhang acted as the principal project leader at Janssen/Johnson & Johnson R&Dand led several innovative projects. He has received the EASL Young Researcher Award. Dr. Zhang earned his PhD in Molecular Medicine at Faculty of Medicine, Technical University of Munich and received his postdoc training at Institute of Medical Virology, German National Research Center for Environmental Health.
Wolfgang Uckert, Prof. Dr.
● Executive Scientific Advisor
SCIENTIFIC ADVISORS
Prof. Dr. Robert Thimme
● Scientific Advisory Board Member
Prof. Dr. Percy A. Knolle
● Scientific Advisory Board Member
Prof. Dr. Jens M. Werner
● Scientific Advisory Board Member
Prof. Dr. Martin Sprinzl
● Scientific Advisory Board Member
Prof. Dr. Lars Zender
● Scientific Advisory Board Member
Prof. Dr. Heiner Wedemeyer
● Scientific Advisory Board Member
Karin Wisskirchen, PhD
Chief Innovation Officer
Dr. Wisskirchen heads SCG’s early research efforts and is also a postdoctoral fellow at the Institute of Virology in Munich. She is a leading expert in the field of adoptive T cell therapy of chronic hepatitis B and HBV-induced hepatocellular carcinoma and has received numerous honors and awards, such as the "GASL price of the YAEL foundation" in 2020, the twice the "Young Investigator Award" of the International Society for Cellular Therapy. Dr. Wisskirchen received her PhD in virology from Technical University of Munich and her diploma in Biology from the Philipps University of Marburg.
The Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) Singapore's lead public sector R&D agency. Through open innovation, A*STAR collaborates with partners in both the public and private sectors to benefit the economy and society in Singapore. SCG has a worldwide licence agreement with A*STAR to develop and commercialise iPSC-derived cell therapy products. In addition, together with the A"STAR’s Bioprocessing Technology Institute (BTI) and Institute of Molecular and Cell Biology (IMCB), SCG collaborates to advance antibody product development and accelerate clinical translation of immune-cell based therapy.
Helmholtz Zentrum München
Helmholtz Zentrum Munich, as part of the biggest research organization in Germany- Helmholtz Association, is a research center with the mission to discover personalized medical solutions for the prevention and treatment of diseases and promote a healthy society. SCG have an exclusive worldwide collaboration and license agreement with Helmholtz Zentrum Munich to develop and commercialize CAR T and TCR T cell therapy products targeting hepatocellular carcinoma and Hepatitis B. We believe this collaboration will form the basis of a strong pipeline of CAR T and TCR T cell therapies.
The Technical University of Munich (TUM)
The Technical University of Munich (TUM) is one of Europe’s top universities. It focuses on engineering sciences, natural sciences, life sciences and forges strong links with industry and scientific institutions across the world. Together with the Helmholtz Zentrum Munich and German Cancer Research Center, SCG entered an exclusive worldwide license agreement to develop bi/multiple specific antibodies against HBV and associated conditions.
German Cancer Research Center (DKFZ)
German Cancer Research Center (DKFZ) is the largest biomedical research institute in Germany focusing on cancer research. Together with the Helmholtz Zentrum Munich and the Technical University of Munich, SCG entered an exclusive worldwide license agreement to develop bi/multiple specific antibodies against HBV and associated conditions.
COLLABORATORS
Shanghai,China
100 Banxia Road, Building 21 Pudong District
Shanghai, China 201318
Other Locations
Munich,Germany
Am Klopferspitz 19
House 5, 1 Floor
82152 Planegg Germany
Singapore
138 Depot Road #04-02 Singapore 109683
Head Office
